内分泌联合曲妥珠单抗在晚期ER+/HER2+乳腺癌中取得了一定的疗效,但pCR率不高。TAnDEM和eLEcTRA研究证实,相比单用芳香化酶抑制剂(AI),加用曲妥珠单抗可改善ER +/HER2+转移性乳腺癌患者的至疾病进展时间(TTP)。Ⅱ期WSG-ADAPT研究评估了...
as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial. SABCS 2024. Abstract: GS1-01.
Cardozo L, Byng D, Drukke CA, et al. Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. Ann Oncol. 2021 Nov 30, DOI:https://doi.org/10.1016/j.annonc.2021.11.014....
ER , HER2 advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomesdoi:10.1002/1878-0261.13416Chen, Jessica W.Jacot, WilliamCortés, JavierKrop, Ian E.Dent, SusanHarbeck, NadiaDe Laurentiis, Michelino...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J101研究则显示治疗HER2+、HR+/HER2-、TNBC的ORR分别为43%、30%和23%[12]。
乳腺癌可根据雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)的表达情况分为4种分子亚型:①管腔A型(ER+、PR+、HER2-),②管腔B型(ER+、PR+、HER2+),③三阴型(ER-、PR-、HER2-),④HER2过表达型(ER-、PR-、HER2+)。其中ER阳性乳腺癌约占所有乳腺癌的70%。尽管大多数患者在最初诊断时尚处...
2023年10月,Annals of Oncology杂志在线发表了题为《Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups》的研究。该研究探讨了口服SERDs在治疗ER+/HER2-转移性乳腺癌中的疗效,特别关注了ESR1基因突变(ESR1mt)...
HER2 overexpressing metastatic breast cancer More than 40,000 women in the United States die each year from metastatic breast cancer. Elucidation of HER2 and its role in malignant transformation has h... David,R.,SpigelHarold,... - 《Current Treatment Options in Oncology》 被引量: 41发表: 20...
Clin. Cancer Res. 25, 2835–284 6.Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer,DOI: 10.1158/1538-7445. FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」 部分图源...
2023年1月27日,美国食品药品监督管理局(FDA)批准了Stemline医疗公司的一种口服选择性雌激素受体降解剂(SERD)——Orserdu(elacestrant),用于治疗既往至少接受一种内分泌治疗后疾病进展的雌激素受体(ER)阳性、HER2阴性、ESR1突变的晚期或转移性乳腺癌的绝经后女性或成年男性。